UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of Report (date of earliest event reported): September 6, 2007
American Oriental Bioengineering, Inc.
(Exact name of registrant as specified in charter)
Nevada
(State or other jurisdiction of incorporation)
| 0-29785 | 84-0605867 | |
| (Commission File Number) | (IRS Employer Identification No.) |
No. 4018, Jintian Road, Anlian Plaza
12 F Suite B02, Futian District
Shenzhen, PRC 518026
(Address of principal executive offices and zip code)
011-86-451-8666-6601
(Registrant’s telephone number including area code)
(Registrant’s former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.01 Completion of Acquisition or Disposition of Assets.
On September 6, 2007, American Oriental Bioengineering, Inc. (“Company”) entered into an Acquisition Agreement with Renson Holdings Limited (“Seller”), a company organized under the laws of the British Virgin Islands, pursuant to which the Company purchased all of the outstanding capital stock of Changchun Xinan Pharmaceutical Group Company Limited (“Xinan”), a corporation organized under the laws of the People’s Republic of China, and a wholly-owned subsidiary of Seller, for a cash purchase price of USD $28.5 million (RMB 215 million). Xinan primarily serves the rural healthcare market with more than 100 plant-based pharmaceutical products in its portfolio.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMERICAN ORIENTAL BIOENGINEERING INC. | ||
| By: | /s/ Yanchun Li | |
| Name: | Yanchun Li | |
| Title: | Chief Financial Officer | |
Dated: September 12, 2007